Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Education Library
  3. ESMO Webinars
  4. ESMO Standalone Webinars

ESMO Webinar: Advanced Urothelial Cancer 2025

Aired live on 19 Feb 2025

ESMO-Webinar-Burgundy-Visual-1000x1000

Login to get immediate access to this content.

Login

Presentation

Download slides

Programme

  • 19 February 2025
Introduction and Welcome
Thomas Powles
Clinical Case of a patient with localised bladder cancer relapsing with metastatic dissemination: overview of epidemiology and practice patterns
Yüksel Ürün
State of the art 1st Line therapy options for patients with advanced urothelial cancer
Thomas Powles
2nd and later line therapies: practice- and biology- informed selection of strategy
Viktor Grünwald
Managing toxicities and optimising tolerability of novel treatment regimens for patients with advanced urothelial cancer
Alison Birtle
Live discussion, Q&A and Conclusions
All speakers
  • powles-thomas

    Thomas Powles

    Chair
    University of London and Barts Cancer Centre
  • urun-yuksel

    Yüksel Ürün

    Speaker
    Ankara University School of Medicine; Department of Medical Oncology
  • grunwald-viktor

    Viktor Grünwald

    Speaker
    University Hospital Essen
    Institute for medical GU Oncology
  • birtle-alison

    Alison Birtle

    Speaker
    Lancashire Teaching Hospitals
    University of Manchester and The University of Central Lancashire

Description

The webinar started with a short welcome and introduction, followed by a presentation of a clinical case displaying localised bladder cancer, relapsing with metastatic dissemination, with an overview of epidemiology and practice patterns. There was then a presentation on state of the art 1st line therapy options for patients with advanced urothelial cancer, followed by a lecture on 2nd and later line therapies. The last lecture focused on managing toxicities and optimising tolerability of novel treatment regimens for patients. The webinar concluded with a live Q&A and discussion.

Learning objectives

  • To improve treatment decisions in the 1st and subsequent lines of therapy of patients with la/mUC due to the rapidly evolving treatment landscape
  • To improve the oncologist’s knowledge regarding the optimal treatment selection
  • To improve the oncologist’s knowledge regarding the management of potential adverse events associated with targeted therapeutic modalities

Supported by

This ESMO product is supported by unrestricted educational grants.

SB-Astellas

The sponsor has had no control or influence on the content of the webinar.

  • powles-thomas

    Thomas Powles

    Chair
    University of London and Barts Cancer Centre
  • urun-yuksel

    Yüksel Ürün

    Speaker
    Ankara University School of Medicine; Department of Medical Oncology
  • grunwald-viktor

    Viktor Grünwald

    Speaker
    University Hospital Essen
    Institute for medical GU Oncology
  • birtle-alison

    Alison Birtle

    Speaker
    Lancashire Teaching Hospitals
    University of Manchester and The University of Central Lancashire

You may also be interested in...

ESMO Guidelines: Real World Cases - Webinar Series

eUpdate – Advanced Urothelial Carcinoma Treatment Recommendations

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.